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Abstract
The Swiss National Guidelines 2013 for chronic obstructive 
pulmonary disease have been revised in order to acknowl-
edge recent progress in diagnosis and management of this 
disease. The resulting new Swiss recommendations are 
based on best evidence from the literature, the Global Initia-
tive for Chronic Obstructive Lung Disease (GOLD) 2018 re-
port and other published national guidelines. Misdiagnosis 
of chronic obstructive pulmonary disease is common and 
means that patients do not always receive optimal treat-
ment. To improve the management of patients with chronic 
obstructive pulmonary disease in Switzerland, these recom-
mendations encourage a more comprehensive assessment 
of patients, based on the combined assessment of symp-
toms, degree of airflow limitation, risk of exacerbation and 
the presence of comorbidities. Recommendations for evi-
dence-based preventive measures, as well as pharmacologi-
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cal and non-pharmacological strategies for the manage-
ment of both stable and acute exacerbations of chronic ob-
structive pulmonary disease are provided in this update.
© 2018 S. Karger AG, Basel
Introduction
National chronic obstructive pulmonary disease 
(COPD) recommendations are a vital tool to assist health 
professionals in keeping abreast of the latest medicines 
and treatment options for patients with the condition. 
With the advent of many new therapies in the last few 
years, an update of the 2013 Swiss guidelines is warrant-
ed to ensure effective management of patients. The up-
date includes stable COPD and acute exacerbation man-
agement recommendations based on the international 
GOLD Global Strategy for the Diagnosis, Management 
and Prevention of COPD 2018 report, published online 
on the GOLD website, as well as best evidence from 
the literature and other published national guidelines in 
Europe (Table 1). The updated GOLD 2018 report pub-
lished broader inclusion criteria, which means there may 
be more patients affected by COPD than previously diag-
nosed. 
Based on the GOLD 2018 report, this update incor-
porates a new definition of COPD, as well as an updated 
ABCD assessment tool that enables inclusion of a broad-
er patient population. A personalized approach is advo-
cated. As before, this update recommends evaluation 
for COPD in individuals with a history of risk factors or 
with dyspnea, chronic cough, or sputum production, 
using a post-bronchodilator forced expiratory volume 
in one second/forced vital capacity (FEV1/FVC) cut off 
ratio less than 70% for diagnosis. However, the role of 
spirometry in the overall management of COPD is 
amended to include a combined assessment that sepa-
rates symptoms, exacerbation history and the patient’s 
overall health. Pharmacotherapy changes for stable 
COPD have been updated to reflect the latest random-
ized controlled trial data, which confirms the benefits of 
fixed dose triple bronchodilator therapy in stable COPD 
patients. Another addition to these recommendations is 
a slight change in the definition of an exacerbation, 
which is simplified and more practical for the clinical 
setting. Non-drug interventions and lifestyle measures 
such as smoking cessation programs, vaccinations and 
pulmonary rehabilitation is recommended, and usage 
of these resources should be maximized in all COPD 
patients.
Definition
COPD is characterized by persistent respiratory 
symptoms and airflow limitation that is due to airway 
and/or alveolar abnormalities usually caused by signifi-
cant exposure to noxious particles or gases [12]. The 
revised GOLD definition of COPD, endorsed by both 
the American Thoracic Society and the European Re-
spiratory Society (ERS), takes into consideration the 
impact of respiratory symptoms and the role of lung tis-
sue and airway abnormalities in the development of 
COPD [12]. 
Burden of Disease
Although COPD is largely a preventable and treat-
able disease, analysis of the incidence of respiratory 
symptoms shows that COPD is a major disease burden 
in Europe [13]. It is often underdiagnosed or misdiag-
nosed in Swiss primary care and hence prevalence and 
mortality figures are significantly underestimated [14, 
15]. Measured airflow obstruction prevalence of up to 
10% for adult patients (GOLD stage ≥2) is estimated 
in the Swiss Study on Air Pollution and Lung Diseas-
es in Adults (SAPALDIA) cohort [16]. This study also 
shows that the prevalence of COPD is largely age de-
pendent. 
Mortality from COPD accounts for almost 50% of all 
respiratory disease deaths in Switzerland [17]. Approxi-
mately 2.6% of all hospitalizations are related to COPD in 
Swiss patients [14]. Cigarette smoking is the most com-
mon risk factor for COPD, but other environmental ex-
posures and host factors may contribute (e.g., occupa-
tional exposures, biomass fuels, α1-antitrypsin deficien-
cy) [12]. Individual susceptibility to infections plays a role 
in exacerbations [12].
COPD is a debilitating and chronic disease that car-
ries a significant and substantial socioeconomic burden 
on individuals and society. Direct COPD-related costs 
increase with disease severity. In Sweden, direct costs 
from COPD are reported as EUR 7,320 for mild, EUR 
8,280 for moderate, EUR 9,230 for severe and EUR 
11,810 for very severe disease [18]. Indirect costs such 
as the inability to work may be affected in individuals 
with the disease [18]. In 2012, the average income of a 
Swedish COPD patient was less than half of what a non-
COPD patient earns (EUR 11,500 vs. EUR 29,000 in 
2012) [18]. 
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Diagnosis
The diagnostic process for COPD should be multidi-
mensional and include a detailed medical history, physi-
cal examination and measurement of airflow obstruction. 
Prompt and accurate diagnosis enables early interven-
tion, therefore, according to the most recent GOLD strat-
egy, a diagnosis of COPD should be considered in any 
patient with a history of exposure to risk factors (e.g., to-
bacco smoking) and/or with dyspnea (progressive, on ex-
ertion or persistent), chronic cough or sputum produc-
tion [12]. Post-bronchodilator spirometry (FEV1/FVC 
ratio < 70%) is required for confirmation of a diagnosis 
[12]. Confirm with repeated spirometry measurements 
Table 1. Overview of European national clinical practice guidelines on chronic obstructive pulmonary disease published from 2007
Country Organization Title of guidelines Number 
of pages
Year of 
publication
England/Wales National Institute for Health and 
Clinical Excellence (NICE)
Chronic obstructive pulmonary disease 
in over 16s: diagnosis and 
management (CG101)
62 2010 [1] 
Germany German Respiratory Society and 
German Society for Pneumology and 
Respiratory Medicine
Guidelines for the diagnosis and 
therapy of COPD
40 2007 [2] 
France Société de Pneumologie de Langue 
Française
Recommendation for the clinical 
practice management of COPD
27 2010 [3] 
The Netherlands Dutch College of General 
Practitioners (NHG)
The NHG guidelines “Adult asthma” 
and “COPD”
2015 [4] 
Finland The Finnish Medical Society  
Duodecim
Diagnosis and pharmacotherapy of 
stable chronic obstructive pulmonary 
disease: the Finnish guidelines
17 2015 [5] 
Poland Polish Respiratory Society Polish respiratory society guidelines 
for chronic obstructive pulmonary 
disease
37 2014 [6] 
Italy AIMAR (Interdisciplinary 
Association for Research in Lung 
Disease), AIPO (Italian Association 
of Hospital Pulmonologists), SIMER 
(Italian Society of Respiratory 
Medicine), SIMG (Italian Society 
of General Medicine)
The clinical and integrated 
management of COPD
19 2014 [7]
Spain Spanish Society of Pulmonology and 
Thoracic Surgery
(SEPAR)
Spanish guideline for COPD 
(GesEPOC). Update 2014
16 2014 [8] 
Czech Republic Czech Pneumological and 
Phthisiological Society
Chronic Obstructive Pulmonary 
Disease: official diagnosis and 
treatment guidelines of the Czech 
Pneumological and Phthisiological 
Society; a novel phenotypic approach 
to COPD with patient-oriented care.
13 2013 [9] 
Portugal Health Ministry, Portugal Diagnosis and Treatment of Chronic 
Obstructive Pulmonary Disease
15 2011 [10]
Switzerland Swiss Respiratory Society Diagnosis and Management of 
Chronic
Obstructive Pulmonary Disease:
The Swiss Guidelines
15 2013 [11]
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the absence or presence of airflow obstruction in patients 
with an FEV1/FVC ratio between 60 and 80%, as this ratio 
may change due to biological variability [12].
Medical History
A focused history should be collected in patients with 
suspected COPD and should include (1) key symptoms 
such as dyspnea, chronic cough, and sputum production; 
(2) smoking habits (including quantification of cumula-
tive smoking history, that is, how many packs per year); 
(3) exposure to other risk factors (i.e., occupational or 
environmental exposures); (4) past medical history, in-
cluding asthma and respiratory infections in childhood; 
(5) family history of COPD or other chronic respiratory 
disease; (6) pattern of symptom development; (7) history 
of exacerbations or previous hospitalizations for respira-
tory disorders; (8) presence of comorbidities, (9) impact 
of disease on patient’s life; (10) opportunities for reducing 
risk factors (e.g., smoking cessation); and (11) family and 
social support [12].
Physical Examination
Diagnosis of COPD cannot be made on clinical signs 
alone, but these may be suggestive of COPD severity [12]. 
The sensitivity and specificity of a physical examination 
in detecting mild to moderate COPD are relatively poor 
due to the slow progressive nature of the disease; there 
may be no clinical signs or symptoms attributable to ag-
ing or smoking [12]. Consequently, COPD is most often 
diagnosed in the advanced stage when physical signs of 
airflow obstruction and pulmonary hyperinflation have 
developed [12]. Chest auscultation may or may not detect 
crackles or wheezing with a prolonged expiratory phase 
[12]. Evidence of fatigue, weight loss and anorexia may be 
noted in severe cases of COPD [12]. Notably, chronic re-
spiratory symptoms may precede airflow limitation and 
may be associated with the development of acute respira-
tory events; symptoms may also exist in patients with 
normal spirometry.
Pulmonary Function Testing
Spirometry should be performed when COPD is 
suspected and remains the most sensitive and impor-
tant test for making a diagnosis of COPD. The GOLD 
guidelines suggest that in patients with a FEV1/FVC 
ratio < 70%, the presence of a post-bronchodilator FEV1 
of ≥80%, 50% to < 80%, 30% to < 50% or < 30% of the 
predicted value, presents a mild, moderate, severe or 
very severe airflow limitation severity in COPD respec-
tively [12].
Combined Assessment
The updated GOLD guidelines recommend a com-
bined assessment approach to group patients accord-
ing to airflow, impact of the patient’s symptoms on dai-
ly living, and patient’s future risk of experiencing an 
exacerbation [12]. The “ABCD” assessment tool has 
been revised to reflect spirometry-confirmed diagno-
sis,  in conjunction with symptoms and exacerbation 
history for prognosis and therapeutic considerations 
(Fig.  1). The ABCD assessment tool allows individu-
al assessment to determine the classification of disease 
severity and hence achieve better stratification of pa-
tients.
Assessment of Severity of Airflow Limitation
The presence of airflow limitation is indicated by a re-
duced post-bronchodilator FEV1/FVC ratio of < 70% and 
an FEV1 of < 80%. The GOLD classification categorizes 
airflow limitation into stages based on post-bronchodila-
tor FEV1 predictions (Table 2).
Assessment of Symptoms
The impact of respiratory symptoms on a patient’s 
life should be assessed by the modified Medical Research 
Council (mMRC) questionnaire and the COPD Assess-
ment Test (CATTM) or the COPD Control questionnaire 
(CCQ®) [12]. Shortness of breath during exercise is one 
of the primary symptoms of COPD, and the mMRC 
dyspnea scale should be used to grade the breathlessness 
according to the level of exertion required to elicit it 
(Table 3) [12]. The CAT and CCQ are simple scoring 
methods that have a broader coverage of the impact of 
COPD on the patient’s daily life and well-being and cor-
relate closely with health status impairment measured 
using the more complex St. Georges Respiratory Ques-
tionnaire [12]. CAT is a standard and validated assess-
ment tool containing 8 items for the evaluation of the 
impact of COPD on health status; each response is grad-
ed 0–5 with a higher score indicating worse health status 
(Table 4) [12]. It has also been translated into several 
languages and can easily be completed online at www.
catestonline.org.
Assessment of Exacerbation Risk
An exacerbation is defined as an acute worsening of 
respiratory symptoms resulting in additional therapy. 
Frequent exacerbations have a high correlation with in-
creased hospitalizations and an increased risk of mortal-
ity. Risk of exacerbation is divided into 4 groups (A, B, C, 
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D; Fig. 1). Patients are deemed to have a high exacerba-
tion risk (group C or D) if they have a history of 2 or more 
exacerbations or more than one exacerbation leading to 
hospitalization in the past year [12]. 
Eosinophilia is a good predictor of viral exacerbations 
[19]. High eosinophil blood counts may predict increased 
exacerbation rates in patients treated with long-acting be-
ta-agonist (LABA) bronchodilators without inhaled cor-
ticosteroids (ICS) [12].
Assessment of Comorbidities
Patients with COPD are frequently affected by comor-
bidities, including cardiovascular disease, skeletal muscle 
dysfunction, metabolic syndrome, osteoporosis, depres-
sion, anxiety and lung cancer. Comorbidities potentiate 
the morbidity of COPD and influence mortality and hos-
pitalizations independently. Routinely monitor and ade-
quately treat comorbidities in all COPD patients. Treat-
ment of comorbidities should not change COPD man-
agement [12]. 
Alpha-1 Antitrypsin Deficiency
Screening for alpha-1 antitrypsin deficiency (AATD) 
is recommended for all patients with diagnosed COPD. 
A low concentration (< 20% normal) is highly suggestive 
of homozygous deficiency. Family members should be 
screened and together with the patient, referred to spe-
cialist centres for advice and management [12]. Almost 
50% of the patients with AATD experience more frequent 
exacerbations than COPD patients without AATD [20]. 
Spirometrically
confirmed
diagnosis
Post-bronchodilator
FEV1/FVC <0.7
≥2
or
>1 leading
to hospital
admission
0 or 1
(not leading
to hospital
admission)
mMRC 0–1
CAT <10
mMRC ≥2
CAT ≥10
FEV1
(% predicted)
Assessment of
airflow limitation
Assessment of
symptoms/risk of
exacerbations
Moderate/severe
exacerbation history
Symptoms
A B
C DGOLD 1
GOLD 2
GOLD 3
GOLD 4
≥80
50–79
30–49
<30
Fig. 1. Revised ABCD assessment tool [12]. 
mMRC, modified Medical Research Coun-
cil questionnaire; CAT, COPD Assessment 
Test. ©GOLD COPD, reproduced with 
permission.
Table 2. Classification of airflow limitation severity in COPD based 
on post-bronchodilator FEV1 (GOLD staging categories) [12]
In patients with FEV1/FVC <70%
GOLD staging spirometric findings
1 (mild) FEV1 ≥80% predicted
2 (moderate) 50% ≤ FEV1 <80% predicted
3 (severe) 30% ≤ FEV1 <50% predicted
4 (very severe) FEV1 <30% predicted
Table 3. The mMRC dyspnea scale
Grade Level of breathlessness
0 No breathlessness, except on strenuous exercise
1 Short of breath when hurrying or walking up a 
slight hill
2 Walks slower than contemporaries on level ground 
because of breathlessness or has to stop for breath 
when walking at own pace
3 Stops for breath after walking 100 metres or after a 
few minutes on level ground
4 Too breathless to leave the house, or breathless when 
dressing or undressing
Adapted from [12]. mMRC, modified British Medical Research 
Council questionnaire.
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In Switzerland, the mean number of individuals with 
AATD is estimated at 7,423 based on a population of 
7.45 million [21]. 
Complementary Investigations
Radiological Imaging
COPD cannot be diagnosed based on a chest X-ray, 
but a chest X-ray may be valuable during the initial eval-
uation to exclude other diseases and to establish the pres-
ence of significant comorbidities such as concomitant 
respiratory, skeletal and cardiac disease [12]. Consider 
CT of the chest not only for the differential diagnosis, 
but  also for detection of concomitant bronchiecta-
sis, screening for lung cancer, assessment for lung-vol-
ume-reduction procedures and lung transplantation 
[12]. 
Lung Volumes and Diffusing Capacity
Pathological changes occurring in COPD can lead to 
static hyperinflation of the lungs. Measurement of lung 
volumes by body plethysmography can help character-
ize COPD severity [12]. Moreover, the evaluation of the 
residual volume is essential to establish the indication 
for lung-volume reduction [11]. Measurement of the 
diffusing capacity of the lungs for carbon monoxide 
(DLCO) may be considered to provide an index of the 
severity of tissue destruction in emphysema [22]. 
Pulse Oximetry 
Pulse oximetry provides a method for rapid assess-
ment of short-term respiratory compromise. It is recom-
mended for all patients with clinical signs suggestive of 
right heart failure or respiratory failure. Pulse oximetry 
may be useful in identifying possible hypoxic patients 
who require supplementary oxygen therapy or in deter-
mining which patients require arterial blood gas mea-
surements [12, 23]. 
Exercise Testing
The objective assessment of exercise capacity in pa-
tients with limited exercise tolerance is a useful tool in 
COPD prognosis, in the assessment of health status, as 
well as, in the assessment of the effectiveness of pulmo-
nary rehabilitation. The paced shuttle walk test and un-
paced 6-min walk test are common test modalities [12]. 
Composite Scores
The BODE index assigns scores to 4 variables (body 
mass index, obstruction, dyspnea and exercise) to give a 
composite score that better predicts mortality than each 
single variable [12]. 
More recently, the B-AE-D index, namely, body mass 
index (B), frequency of severe acute exacerbations of COPD 
(AE) and mMRC dyspnea severity (D) has been identified 
as including the most suitable composite markers for sim-
ple and accurate risk assessment in COPD [24]. B-AE-D, 
plus copeptin, if available, is a COPD-specific prognostic 
Table 4. COPD assessment test (CAT) [12]
Low impact Score High impact
0 1 2 3 4 5
I never cough I cough all the time
I have no phlegm (mucus) in my chest at all My chest is completely full of phlegm (mucus)
My chest does not feel tight at all My chest feels very tight
When I walk up a hill or one flight of stairs 
I am not breathless
When I walk up a hill or one flight of stairs 
I am very breathless
I am not limited doing any activities at home I am very limited doing activities at home
I am confident leaving my home despite my 
lung condition
I am not at all confident leaving my home because 
of my lung condition
I sleep soundly I do not sleep soundly because of my lung condition
I have lots of energy I have no energy at all
Scores <10 are uncommon in the diagnosis of COPD patients and scores ≥10 are very uncommon in healthy persons.
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index that was not inferior to BODE for predicting 2-year 
all-cause mortality (c-statistic: 0.74, 0.77, 0.69, 0.72 and 
0.63, respectively; Hosmer-Lemeshow test all p > 0.05) [24]. 
Differential Diagnosis
It can be challenging to differentiate between COPD and 
asthma with chronic airflow limitation in some patients 
(Table 5). In patients with common features of both asthma 
and COPD, a diagnosis of Asthma-COPD Overlap Syn-
drome or Asthma-COPD Overlap (ACO) may be given. As 
the role of biologics in the treatment of ACO is still being 
defined, ACO should be treated according to the dominant 
phenotype [25]. Additional potential differential diagnoses 
are easier to distinguish from COPD and include congestive 
heart failure, bronchiectasis, tuberculosis, obliterative 
bronchiolitis and diffuse panbronchiolitis [12]. 
Methodology
Levels of evidence assigned to management recom-
mendations are based largely on the GOLD report, which 
uses the evidence-ranking system of the US National 
Heart, Lung and Blood Institute, and was used in the pre-
vious Swiss guidelines (Table 6) [12]. 
Preventive Therapy
Prevention and appropriate preventive therapy can al-
leviate the impact of COPD on public health [12]. 
Smoking Cessation
Smoking cessation remains the most effective inter-
vention that reduces lung function decline in COPD and 
therefore should be the top priority for all COPD patients 
(Evidence A) [12]. Studies show that smoking cessation 
slows the annual decrease of FEV1 to a rate comparable 
to that of non-smokers [30]. In a Swedish study of COPD 
smokers, the long-term smoking cessation success rate 
(after 3 years) was 38% for subjects who took part in 
smoking cessation groups, compared to only 10% for sub-
jects in the control group [31]. A systematic review shows 
that more intensive recruitment strategies that require in-
creased patient contact, improve recruitment of patients 
into smoking cessation programmes (Evidence A) [32]. 
Smoking cessation rates also improve when smokers are 
provided with pharmacotherapy [33]. 
Pharmacotherapy, including nicotine replacement ther-
apy, is effective in supporting smoking cessation attempts 
and should be prescribed in the absence of contraindica-
tions [12]. A meta-analysis evaluating 7,332 patients with 
COPD reported that the combination of cognitive behav-
ioural therapy (CBT) and nicotine replacement therapy was 
Table 5. Differential diagnosis of COPD and asthma [12, 26–29]
Suggestive features Diagnosis
asthma COPD
Age of onset Early onset (typically in childhood); late-onset 
asthma is often not Th2 mediated
Onset in mid-life
History Family history of asthma; co-existence of obesity History of tobacco smoking or exposure 
to other types of smoke
Th2 high vs. Th2 
low disease
Predominately a Th2-driven disease (with 
exception of late-onset asthma), resulting in 
increased IgE levels as well as blood and sputum 
eosinophil count; eosinophils may decrease in 
number in controlled asthma
Predominately a neutrophil-driven disease 
(Th2-low disease); eosinophil count may be 
increased in some patients
Pattern of symptoms Symptoms vary widely day-to-day; worse at 
night/early morning
Slowly progressive symptoms
Allergies, rhinitis and/or 
eczema
Concomitant allergy, rhinitis and/or eczema 
may be present
Not associated with allergies, rhinitis or  
eczema
FeNO FeNO is highest in asthma FeNO is lowest in COPD
FeNO, fractional exhaled nitric oxide; IgE, immunoglobulin E; Th2, type 2 helper T-cell.
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the most effective type of intervention (OR 5.08; p < 0.0001) 
compared to CBT alone (OR 2.8; p = 0.001) or compared to 
CBT combined with an antidepressant (OR 3.32; p = 0.002) 
(Evidence A) [34].
Electronic cigarette products are becoming increas-
ingly popular [35]. However, their efficacy and safety are 
not well defined and thus their widespread use is not ad-
vocated [12]. Varenicline [36], bupropion [37] and nor-
triptyline [38] are recommended in conjunction with 
supportive intervention programmes to increase long-
term smoking cessation rates (Evidence A) [12, 38]. Fur-
thermore, smoking reduces, at least partially, the impact 
of ICS on FEV1 and peak expiratory flow [39].
Vaccinations
Patients with COPD are particularly vulnerable to in-
fluenza, with evidence for increased incidence and sever-
ity of infection [40]. Influenza vaccines are recommended 
to reduce serious illness and mortality in COPD patients 
[12]. A Cochrane review reported that an inactivated in-
fluenza vaccine reduces the incidence of influenza-relat-
ed respiratory infections (Evidence B) [41]. Patients with 
COPD who were administered an inactivated influenza 
vaccine experienced significantly fewer exacerbations per 
year than patients with COPD who were administered a 
placebo [40]. 
A pneumococcal vaccination provides some protection 
against community-acquired pneumonia (CAP) and is 
recommended for all COPD patients ≥65 years of age [12]. 
For younger COPD patients, the vaccination is recom-
mended if significant comorbidities, such as chronic heart 
or lung disease, are present [12]. The Federal Office of 
Public Health recommends a single dose of conjugated 
13-valent vaccine (Prevenar-13), with no booster doses 
[41]. Pneumococcal polysaccharide vaccine (Pneumovax) 
is no longer recommended because of limited efficacy and 
because antibody levels may diminish with repeat doses 
(“immune exhaustion”). A recent systematic review 
showed that when COPD patients were given the pneu-
mococcal vaccine, they had a lower likelihood of develop-
ing CAP compared to COPD patients receiving a control 
substance (OR 0.62, 95% CI 0.43–0.89; 6 studies, n = 1,372; 
Evidence B) [42]. Pneumococcal vaccination significantly 
reduced the likelihood of a COPD exacerbation (OR 0.60, 
95% CI 0.39–0.93; 4 studies, n = 446; Evidence B) [42]. 
Pharmacological Management of Stable COPD
None of the existing medications for COPD has been 
conclusively shown to modify the long-term decline in 
lung function that is the hallmark of this disease [12]. Spe-
Table 6. Description of levels of evidence
NHLBI evidence 
category
Sources of evidence Definition
A Randomized controlled trials 
(RCTs). Rich body of high quality 
evidence without any significant 
limitation or bias
Evidence is from endpoints of well-designed RCTs that provide a consistent 
finding in the population for which the recommendation is made without 
any important limitations. Category A requires high quality evidence from 
≥2 clinical trials involving a substantial number of subjects, or a single high 
quality RCT involving substantial numbers of patients without any bias
B RCTs with important limitations. 
Limited Body of Evidence
Evidence is from RCTs that include only a limited number of patients, 
post-hoc or subgroup analysis of RCTs, or meta-analysis of RCTs. In 
general, category B applies when few randomized trials exist, or important 
limitations are evident (methodologic flaws, small numbers, short duration, 
undertaken in a population that differs from the target population of the 
recommendation, or the results are somewhat inconsistent)
C Non-randomized trials, 
observational studies
Evidence is from outcomes of uncontrolled or non-randomised trials or 
from observational studies
D Panel consensus, judgement Provision of guidance is deemed valuable but clinical literature addressing 
the subject is insufficient. 
The panel consensus is based on clinical experience or knowledge that does 
not meet the above criteria
NHLBI, National Heart, Lung, and Blood Institute.
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cifically designed trials are required to confirm the post 
hoc evidence of such an effect with long-acting broncho-
dilators and/or ICS [12]. Until then, the main goals with 
current pharmacotherapy continue to reduce symptoms, 
reduce frequency and severity of exacerbations and im-
prove exercise tolerance and health status [12]. 
Treatment should be individualized. Medication 
choice depends on availability, cost, the patient’s prefer-
ence and clinical response weighed against the side effects 
[12]. Existing guidelines advocate the use of long-acting 
bronchodilators as the frontline therapy for COPD, fol-
lowed by dual combination long-acting bronchodilation 
if symptoms persistent and regular inhaled corticosteroid 
therapy is administered as an adjunct in patients experi-
encing frequent exacerbations. However, the latest long-
term data reports that a single inhaler triple therapy with 
ICS/LABA/long-acting anti-muscarinic agent (LAMA) is 
superior to standard therapy with a dual combination 
ICS/LABA or LAMA therapy [43] or tiotropium alone in 
stable COPD patients [43, 44]. Moreover, escalation from 
an ICS/LABA or LAMA combination to triple therapy 
(ICS/LABA/LAMA) using a single inhaler could improve 
patient adherence to treatment [43, 44]. Addition of 
LAMA to ICS/LABA could improve lung function and 
patient-reported outcomes [12].
Bronchodilators
Inhaled bronchodilators are commonly used in the 
management of airflow obstruction because they exert a 
direct relaxant effect on bronchial smooth muscle cells, 
thereby alleviating bronchial obstruction and airflow lim-
itation, reducing hyperinflation and improving exhala-
tion and exercise performance (Evidence A) [45]. 
The inhalation method is preferred above oral broncho-
dilators because it maximizes the bronchodilator effect on 
the airways while minimizing side effects (Evidence A) 
[12]. There are 3 major classes of inhaled bronchodilators: 
(1) beta-2-adrenergic agonists (both short- and long-act-
ing), (2) muscarinic receptor antagonists (both short- and 
long-acting) and (3) systemic phosphodiesterase inhibitors 
(methylxanthines). Relaxation of bronchial smooth muscle 
is caused by blocking acetylcholine activity at the receptor 
(muscarinic antagonists) or stimulating the G-protein-
coupled receptor (beta-2-agonists) [46]. Recent guidelines 
published by the American College of Physicians (ACP), 
American College of Chest Physicians (ACCP), American 
Thoracic Society and ERS do not support bronchodilator 
treatment in asymptomatic COPD patients [47]. 
Short acting beta-2-agonists (SABAs) and muscarinic 
antagonists (SAMAs) are equally effective and used for 
both acute and chronic management of COPD. Regular 
and as-needed use of SABAs and SAMAs improve FEV1 
and respiratory symptoms (Evidence A) [12]. SABAs 
have a short duration of action of 4–6 h [12].
A fixed-dose combination of any LABA and LAMA 
should be considered above monotherapy (Evidence A) 
[12]. Regardless of the drugs used, LAMA/LABA fixed-
dose combinations are generally more effective than the 
respective monotherapies in terms of improvement in 
trough FEV1, transitional dyspnea index (TDI) and St. 
Georges Respiratory Questionnaire scores [48]. Com-
pared to treatment with a LABA, LAMA monotherapy 
has a greater impact on reducing exacerbation rates (Evi-
dence A) and hospitalizations (Evidence B) [12].
A post hoc analysis of the TONADO® studies showed 
that the once-daily combination of LAMA/LABA (tiotro-
pium/olodaterol) significantly improved lung function in 
GOLD II, GOLD III and GOLD IV patients, compared to 
tiotropium alone, irrespective of whether patients had re-
ceived prior LAMA or LABA maintenance treatment 
[49]. Further subgroup analyses suggested that this com-
bination should be considered for maintenance therapy 
in patients with moderate to severe COPD [50]. 
In general, LABAs and LAMAs are prescribed on a 
regular basis, as maintenance therapy, to improve lung 
function, dyspnea and health status and to reduce exac-
erbation rates (Evidence A) [12]. Twice-daily LABAs 
such as salmeterol and formoterol have an extended du-
ration of action that is maintained for 12 h after single 
dose inhalation [51]. Both SABAs and LABAs are gener-
ally well tolerated but may cause resting sinus tachycardia 
and tremor [52].
Head-to-head trials show that LAMAs are superior to 
SAMAs for maintenance therapy [53]. LAMA (tiotropi-
um) treatment shows a greater effect on exacerbation 
rates in clinical trials compared to once-daily LABA (in-
dacaterol) treatment [54]. Dry mouth is one of the most 
common side effects encountered with LAMAs, attribut-
able to its anticholinergic action [55]. Adverse event rates 
are similar to placebo in clinical trials [52]. 
Methylxanthines
Theophylline is a nonspecific phosphodiesterase in-
hibitor that can improve lung function, arterial blood gas 
tensions and walking distance compared to placebo [56]. 
It has a modest bronchodilator effect on FEV1 and FVC 
in moderate to severe COPD [57]. Theophylline in com-
bination with beta-2-agonists improves dyspnea more 
than theophylline monotherapy [58]. In a study by Thom-
as et al. [59], theophylline plus salbutamol significantly 
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improves FEV1 by 31.3% compared to only 13.5 and 
16.2% with the monotherapies respectively. However, 
theophylline combined with beta-2-agonists is non-supe-
rior to the use of beta-2-agonists alone [58].
Inhaled Corticosteroids
Compared to placebo, ICS reduces post-bronchodila-
tor FEV1 and exacerbation rate but has no significant ef-
fect on mortality [60]. A systematic review, which includ-
ed data from the large TORCH (TOwards a Revolution in 
COPD Health) study, shows a smaller improvement in 
lung function (prebronchodilator FEV1) with ICS com-
pared to LABA (MD –18.99 mL; 95% CI –37.46 to –0.52) 
and the risk of pneumonia is significantly greater with 
ICS than with LABA (OR 1.38; 95% CI 1.10–1.73) [61]. 
The combination LABA/ICS potentiates the positive ef-
fects of the ICS therapy, thus long-term monotherapy 
with ICS is not recommended for stable COPD (Evi-
dence A) [12]. A meta-analysis of several studies evaluat-
ing the combination LABA/ICS shows a significant de-
crease in exacerbation rate and mortality compared to 
placebo [62]. 
Data from the OPTIMO (Real-Life study On the aP-
propriaTeness of treatment In MOderate COPD patients) 
[63] and WISDOM (Withdrawal of Inhaled Steroids dur-
ing Optimized Bronchodilator Management) [64] trials 
shows that gradually withdrawing ICS therapy in select-
ed  patients with stable COPD at low risk of exacerba-
tion does not increase the risk for exacerbations. With-
drawal of ICS therapy has been suggested in GOLD III 
COPD patients with normal blood eosinophil count 
(<  150  eosinophils/mm3) and a limited history of exacer-
bations (< 2 exacerbations per year) [65, 66]. 
In the FLAME trial, the first large, randomized, con-
trolled head-to-head trial assessing combination LABA/
LAMA versus combination LABA/ICS in COPD pa-
tients with a history of exacerbations, indacaterol-gly-
copyrronium (LABA/LAMA) therapy was superior to 
salmeterol-fluticasone (LABA/ICS) therapy in prevent-
ing exacerbations, improving lung function and health-
related quality of life in COPD patients [67]. However, 
the IMPACT study, which randomised over 10,000 pa-
tients with COPD to LAMA/LABA/ICS (umeclidinium, 
vilanterol, fluticasone furoate) LAMA/LABA (umecli-
dinium, vilanterol) and LABA/ICS (vilanterol, flutica-
sone furoate) for 52 weeks, showed superior outcomes 
for the combination LABA/ICS as compared to the dual 
bronchodilation with LABA/LAMA [70]. The fact that 
most patients were on ICS before inclusion and that 
“history of asthma” was not an exclusion criteria for the 
IMPACT study could partially explain the superiority of 
LABA/ICS versus LAMA/LABA in IMPACT as much 
as the exclusion of all patients deteriorating during the 
run-in phase (on LAMA only) of FLAME could explain 
the superiority of dual bronchodilation versus LABA/
ICS in that trial. In addition, it is also tempting to hy-
pothesize that the differences in the particular broncho-
dilators used in FLAME (indacaterol vs. salmeterol) 
could additionally account for the differences between 
both regimens. There is consensus that not all patients 
with COPD will benefit from ICS. Those with more se-
vere disease as assessed by airflow obstruction or respi-
ratory symptoms, those with asthmatic features, as well 
as those with higher circulating eosinophils counts 
might profit the most from ICS [12]. Further random-
ized, prospective studies are needed to validate recom-
mendations related to specific patient populations.
The recent PREVENT study, a recent randomized, 
placebo-controlled trial including GOLD II-IV patients 
explored whether increasing the dose of an already estab-
lished combination treatment (LABA/ICS) at the onset of 
an upper respiratory tract infection (URTI) could reduce 
the incidence of subsequent COPD exacerbations for the 
following 21 days, compared to staying on the low-dose 
LABA/ICS [68]. Patients receiving low-dose formoterol 
(12 μg/day) and budesonide (400 μg/day) doubled the 
doses of LABA/ICS for 10 days following the onset of 
URTI symptoms. The risk for the development of a severe 
exacerbation (hospital admission) within 21 days of a 
URTI was significantly decreased by 72% compared to 
the placebo group. COPD patients with more severe dis-
ease (FEV1 < 50%) or at higher risk (GOLD C and D) also 
showed a reduction in the risk of exacerbation. Thus, for 
the first time, a study has shown that hospital admissions 
can be prevented by targeting URTIs with increased short 
term LABA/ICS. 
Triple Inhaled Therapy
A randomized study by Aaron et al. [69] showed that 
combined therapy with fluticasone-salmeterol plus tiotro-
pium may have beneficial effects on quality of life, lung 
function and hospitalizations without an increase in seri-
ous adverse events. Long-term data from the TRILOGY 
(Single Inhaler Triple Therapy Versus Inhaled Corticoste-
roid Plus LABA Therapy for COPD) [43] and TRINITY 
[44] trials demonstrates that single-inhaler triple therapy 
(ICS/LAMA/LABA) has the propensity to simplify medi-
cation regimens, provide greater efficacy, reduce exacer-
bations and has a greater effect on health-related quality 
of life than standard treatment. The primary results of the 
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TRILOGY study showed a statistically significant im-
provement in pre-dose FEV1 in the triple therapy group 
of 0.081 L (p < 0.001) and 2-h post-dose FEV1 of 0.117L 
(p < 0.001) [43]. Adverse events were similar between tri-
ple and dual study groups and were typically mild to mod-
erate in severity [43]. TRINITY is a multicentre study 
evaluating triple therapy in adult patients with severe or 
very severe COPD [44]. Patients were randomized to 1 of 
3 treatment regimens: LAMA alone (tiotropium), fixed 
triple therapy ICS/LABA/LAMA (beclomethasone/for-
moterol/glycopyrronium), or triple therapy with ICS/
LABA (beclomethasone/formoterol) plus LAMA (tiotro-
pium) taken separately [44]. The fixed triple combination 
demonstrated a reduction in moderate and severe exacer-
bations compared to tiotropium (rate ratio 0.80 [95% CI 
0.69–0.92]; p = 0.0025). Non-inferiority between the fixed 
dose triple therapy and dual combination plus tiotropium 
was demonstrated, with a mean difference in pre-dose 
FEV1 of –0.003 L (95% CI –0.033 to 0.027) [44]. Recently, 
triple therapy with LAMA/LABA/ICS proved to be supe-
rior to dual bronchodilator therapy with LAMA/LABA, 
decreasing exacerbation rate by 15% and showing no 
 association with an increased risk of pneumonia. The 
 IMPACT study confirmed superior outcomes for the tri-
ple therapy, LAMA/LABA/ICS (umeclidinium, vilanter-
ol, fluticasone furoate) as compared to LAMA/LABA 
(umeclidinium, vilanterol) and LABA/ICS (vilanterol, 
fluticasone furoate) including the rate of moderate or se-
vere exacerbation (0.91 vs. 1.21 and 1.07 per year, respec-
tively) [70]. Mortality was also significantly reduced in pa-
tients receiving the triple therapy [70]. The incidence of 
pneumonia was, however, significantly increased in pa-
tients receiving an ICS [70]. Therefore, triple therapy 
should be considered in selected, symptomatic patients 
with severe airflow obstruction and at least one exacerba-
tion in the previous year [71].
Oral Corticosteroids
Oral corticosteroids may improve FEV1 in stable 
COPD [72]; however; its long-term use is harmful for sta-
ble COPD patients because muscle strength and pulmo-
nary function deteriorate after high doses of systemic cor-
ticosteroids. A study by Horita et al. [73] reported that 
long-term oral corticosteroids may increase the mortality 
of severe and very severe COPD patients. 
Phosphodiesterase-4 Inhibitors
Roflumilast improves lung function and decreases ex-
acerbations (frequency and hospitalizations) in patients 
with severe to very severe COPD [74, 75]. The REACT 
(Roflumilast in the Prevention of COPD Exacerbations 
While Taking Appropriate Combination Treatment) 
study showed that in COPD patients at risk of frequent or 
severe exacerbations and hospitalizations, receiving inha-
lation combination ICS/LABA therapy or triple therapy 
(LAMA/ICS/LABA), roflumilast significantly reduced 
the rate of severe exacerbations by 24.3% (p = 0.0175) and 
hospital admissions by 23.9% (p = 0.0209) [74]. 
Antibiotics
Although prophylactic antibiotics are not recom-
mended for routine use in patients with COPD, they may 
be considered in certain situations [12]. A randomized 
controlled study by Albert et al. reported that adding dai-
ly azithromycin (250 mg) to the usual treatment for 
1  year decreased the frequency of exacerbations and 
 improved quality of life in patients with COPD aged 
≥40  years who had an increased risk of exacerbations 
(but without hearing impairment) [76]. A more recent 
study by Uzun et al. [77] confirmed the improvement in 
exacerbation rate in patients with COPD who received 
previous treatment for 3 or more exacerbations in the 
preceding year. Thus, azithromycin 500 mg 3 times a 
week might be considered in patients with severe airflow 
obstruction and recurrent, frequent exacerbations. Due 
to the potential side effects (emergence of antimicrobial 
resistance, gastrointestinal and ontological complaints) 
the indication for this therapy should be evaluated by a 
pneumologist.
Alpha-1 Antitrypsin Augmentation Therapy
It is suggested that this therapy may be considered for 
never-smokers or ex-smokers with an FEV1 of 35–60% 
predicted (Evidence B) [12]. Patients with severe heredi-
tary AATD and established emphysema may also be can-
didates for alpha-1 antitrypsin augmentation therapy 
(Evidence B) [12].
Mucolytic and Antioxidant Agents
Antioxidant mucolytics should be considered in se-
lected patients (Evidence A) [12]. Two meta-analyses 
demonstrate that long-term mucolytic or antioxidant 
therapy (e.g., N-acetylcysteine) may significantly reduce 
the frequency of exacerbations in COPD patients [78, 
79]. Improvement of lung function is seen in the 1-year 
HIACE trial in patients with stable COPD treated with 
high-dose N-acetylcysteine (600 mg twice daily) [80]. The 
most benefit is observed in those with frequent exacerba-
tions and only with a high dose of N-acetylcysteine (1,200 
mg per day) [81].
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Immunomodulators
The lyophilized bacterial extract OM-85 BV is an im-
munomodulator used for preventing exacerbations [82]. 
There is no conclusive evidence as to its efficacy. One me-
ta-analysis showed that both exacerbation and incidence 
rate of patients using antibiotics were reduced in COPD 
patients receiving OM-85 BV compared to placebo by 
20% (relative risk 0.80, 95% CI 0.65–0.97) and 39% (rela-
tive risk 0.61, 95% CI 0.48–0.77) [83], respectively, while 
a previous meta-analysis found only a numerical trend in 
favour of OM-85 BV in the exacerbation rate (relative risk 
0.83, 95% CI 0.65–1.05) [82]. Further trials are required 
to confirm the effectiveness of OM-85 BV in patients with 
COPD [82, 83].
EPs® 7630 is an extract from the roots of the flowering 
plant Pelargonium sidoides effective for the treatment of 
URTIs and acute bronchitis. The safety and efficacy of 
EPs® 7630 for the treatment of patients with stable COPD 
GOLD II/III is demonstrated in a multicentre, placebo-
controlled double-blind study. EPs® 7630 prolongs the 
median time to exacerbation compared to placebo (57 vs. 
43 days; p = 0.005) [84]. The number of moderate exacer-
bations during the treatment period is significantly lower 
in the EPs® 7630 group compared to the placebo group 
(0.38 [SD 0.53] vs. 0.86 [0.68]; p < 0.001) [85]. Treatment 
with EPs® 7630 also results in a reduction in antibiotic 
use and improvement in quality of life [84–86]. Further 
trials are required to confirm the effectiveness of EPs® 
7630 in patients with COPD.
Oxygen Therapy
Long-term oxygen therapy (> 16 h per day) is recom-
mended to increase the survival in stable COPD pa-
tients with arterial hypoxemia (PaO2 ≤55 mm Hg or 
SaO2 ≤88%, or 55< PaO2 < 60 mm Hg or SaO2 = 88%), 
if there is evidence of pulmonary hypertension, periph-
eral oedema suggesting congestive cardiac failure, or 
polycythemia (haematocrit > 55%; Evidence A) [12, 87]. 
In a systematic review of 6 randomized controlled trials, 
a significant improvement in mortality over 5 years is 
observed (OR 0.42, 95% CI 0.18–0.98) for the subjects 
receiving oxygen therapy compared to those who do not 
[87]. 
Pulmonary Rehabilitation
Pulmonary rehabilitation is one of the key recom-
mended approaches in the treatment of COPD (Evi-
dence A) [12]. It is “a comprehensive intervention based 
on thorough patient assessment followed by patient tai-
lored therapies that include, but are not limited to, exer-
cise training, education, self-management intervention 
aiming at behaviour change, designed to improve the 
physical and psychological condition of people with 
chronic respiratory disease and to promote the long-term 
adherence to health-enhancing behaviours” [12, 88]. A 
meta-analysis of 65 randomized controlled trials involv-
ing 3,822 participants concludes that pulmonary rehabil-
itation, including inspiratory muscle training, improves 
muscle strength, endurance, exercise capacity, dyspnea, 
quality of life and emotional function and enhances the 
sense of control that individuals have over their condition 
[89]. Pulmonary rehabilitation should be considered for 
most patients with COPD, although it is especially effec-
tive in patients with moderate to severe disease [12]. Pro-
grammes lasting 6–8 weeks are recommended for opti-
mal benefit [12]. 
Interventional Therapy
Bronchoscopic interventions in COPD patients with ad-
vanced emphysema are aimed at reducing hyperinflation 
and end-expiratory lung volume and at improving exercise 
tolerance, health status and lung function 6–12 months fol-
lowing treatment [12]. The 2 recommended bronchoscop-
ic procedures are endobronchial valves (Evidence B) and 
lung coils (Evidence B) [12].
Lung volume reduction surgery improves quality of 
life and survival in patients with severe emphysema and 
low post-rehabilitation exercise capacity (Evidence A) 
[12]. However, lung volume reduction surgery is associ-
ated with higher costs compared to health-care programs 
that do not include surgery [12]. Bullectomy results in 
decreased dyspnoea, improved lung function and exer-
cise tolerance [12].
Lung transplantation improves quality of life and 
functional capacity in selected patients (Evidence C) [12].
Pharmacologic Treatment Algorithms
The GOLD guidelines propose new treatment algo-
rithms for the initiation and subsequent escalation/de-es-
calation of pharmacological management of stable COPD 
according to the individualized assessment of symptoms 
and risk of exacerbations (groups A–D) [12]. A summary 
is shown in Figure 2. Bronchodilators are recommended as 
the initial treatment for all groups (Evidence A) [12]. Long-
acting bronchodilators are preferred over short-acting 
agents except for patients with only occasional dyspnea 
(Evidence A) [12]. Patients in group B with persistent dys-
pnea should escalate to 2 bronchodilators (Evidence A) 
[12]. For patients in group C, a second long-acting bron-
chodilator is the preferred treatment option if exacerba-
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tions persist [12]. Alternatively, LABA/ICS can be consid-
ered (Evidence A) [12]. For group D, treatment can be es-
calated to triple inhaled therapy (ICS/LAMA/LABA) [12]. 
Treatment with a macrolide antibiotic (azithromycin 3× 
per week) can be considered in former smokers, particu-
larly in frequent exacerbators and those requiring long-
term oxygen therapy (Evidence B) and PDE-4 inhibitors 
(roflumilast) in patients with an FEV1 < 50% predicated 
and chronic bronchitis (Evidence B) [12]. 
Alpha-1 antitrypsin augmentation therapy may be 
considered for patients with severe hereditary AATD and 
established emphysema (Evidence B) [12]. Treatment op-
tions not recommended for any group include long-term 
ICS monotherapy (Evidence A), long-term therapy with 
oral corticosteroids (Evidence A) and theophylline, un-
less other long-acting bronchodilators are unavailable 
(Evidence B) [12]. 
Management of Exacerbations
An acute exacerbation of COPD (AECOPD) is defined 
as an acute worsening of respiratory symptoms, and this 
results in additional therapy [12]. Some COPD patients 
are particularly susceptible to frequent exacerbations (de-
fined as 2 or more exacerbations per year), and these pa-
tients have a worse health status and a higher morbidity 
than patients with less frequent exacerbations do. The 
Further
exacerbation(s)
Further
exacerbation(s)
LAMA LAMA + LABA
LAMA + LABA
Continue, stop or
try alternative class
of bronchodilator
A bronchodilator
Evaluate
effect
Persistent
symptoms
A long-acting bronchodilator
(LABA or LAMA)
LAMA + ICS
LAMA
+ LABA
+ ICS Persistent
symptoms/further
exacerbation(s)
Group C Group D
Group A Group B
LAMA + LABA
Consider roflumilast
if FEV1 <50% predicted
and patient has
chronic bronchitis
Consider macrolide
(in former smokers)
Further
exacerbation(s)
LABA + ICS
LAMA
Fig. 2. Pharmacologic treatment algorithms by GOLD Grade [12].  Preferred treatment = --->. In patients with 
a major discrepancy between the perceived level of symptoms and severity of airflow limitation, further evalua-
tion is warranted.
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goals of management of AECOPDs are to minimize the 
impact of the current exacerbation and to prevent the de-
velopment of subsequent events [12]. 
AECOPDs impose a substantial burden on the health-
care system and cause considerable morbidity, hospi-
tal  admissions, and mortality. The risk of mortality in-
creases by 30–43% within 12 months following an acute 
COPD exacerbation. Among individuals with COPD, 
some patients are prone to frequent exacerbations while 
others remain relatively protected [89]. Approximately 
70–80% of COPD exacerbations are triggered by bacterial 
and viral infections (especially rhinovirus), but air pollu-
tion can also be an induction factor [90, 91]. Frequency of 
exacerbations is one of the most important determinants 
of health-related quality of life in patients with COPD.
In Switzerland, patients with AECOPDs have a pro-
longed hospital stay compared to patients in other 
 European countries (11.3 vs. 8.7 days; p < 0.001) [92]. 
Moreover, the risk of in-hospital death (5.4%) is slightly 
elevated compared to other European countries (4.9%) 
but overall mortality is lower (8.1 vs. 10.9%, respective-
ly) [92]. The recent European COPD audit recommends 
at least a (venous) blood gas analysis in every patient 
admitted to hospital with suspected severe exacerbation 
of COPD [92]. Currently, the number of arterial blood 
gas samples taken to assess the severity of exacerbations 
in Switzerland is comparable to other European coun-
tries (85.6 vs. 84.1%, respectively) [92]. Spirometry 
should also be performed before a patient is discharged 
from hospital or at least 4–6 weeks thereafter [92].
Preventive Strategies
Almost half (43%) of Swiss COPD patients admitted 
to hospital due to an acute exacerbation are smokers in 
contrast to 31% in other European countries (p < 0.001) 
[92]. Based on the recommendations of the European 
COPD audit, smoking cessation should be offered to 
COPD patients admitted to hospital for an exacerbation 
[92]. In addition, patients should be informed about in-
fluenza and pneumococcal vaccinations [92].
Bronchodilation
The mainstay of AECOPD treatment is bronchodila-
tion with SABAs, with or without short-acting anticho-
linergics (Evidence C) [12]. Medical staff should be 
trained in the administration of inhaled and nebu-
lized bronchodilators in all Swiss hospitals [92]. A re-
cent European audit suggests that only 79% of patients 
in Swiss hospitals receive this treatment for exacerba-
tions at admission [92]. 
Systemic Glucocorticosteroids
High-quality evidence supports the treatment of 
 AECOPD with systemic glucocorticosteroids (oral or 
parenteral route) (Evidence A) [92, 93]. In diagnosed pa-
tients, systemic glucocorticosteroids reduce the likelihood 
of treatment failure and relapse by one month, shorten the 
hospital stay in patients not requiring assisted ventilation 
and provide earlier improvement in lung function and 
symptoms [12, 93]. Glucocorticosteroid treatment should 
not be given for more than 5–7 days [94]. 
Antibiotics
AECOPDs should not be treated with antibiotics, un-
less a bacterial infection is suspected, or the patient re-
quires treatment in the intensive care unit (Evidence B) 
[12, 95]. In acute exacerbations of COPD with increased 
cough and sputum purulence, the use of antibiotics re-
duces the short-term risk of mortality by 77% and de-
creases the risk of treatment failure by 53% [96]. In non-
febrile exacerbations, antibiotics do not reduce treatment 
failure at 28 days [97] do not prolong the exacerbation-
free time [98]. Antibiotic treatment should not exceed 
5–7 days during an AECOPD [12, 99]. A serum procalci-
tonin-guided approach can reduce use and exposure to 
antibiotics without impacting clinical outcomes such as 
re-exacerbation, need for hospitalization or mortality 
(Evidence A) [100, 101].
Other Recommended Pharmacological Treatments  
for AECOPD
Methylxanthines are not recommended for treatment 
of AECOPD in the GOLD guidelines (Evidence B) [12, 
102]. A meta-analysis evaluating the role of intravenous 
aminophylline during an AECOPD did not find any ben-
eficial effect in terms of improvement of pulmonary func-
tion or symptoms [102]. 
Oxygen Therapy
Oxygen therapy is a key component of hospital treat-
ment for an exacerbation [12]. Titrating oxygen therapy 
to ≥90% saturation is recommended in patients with an 
AECOPD to avoid hypoxemia and to reduce the risk of 
oxygen-induced hypercapnia [12, 103]. In Switzerland, 
approximately 93.1% of AECOPD patients receive oxy-
gen therapy on admission to hospital.
Non-Pharmacological Therapy
Non-invasive ventilation (NIV) is the standard of 
care to decrease intubation rates and mortality in pa-
tients hospitalized with AECOPD and acute respiratory 
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failure [12]. NIV should be the first mode of ventilation 
used in COPD patients with acute respiratory failure 
who have no absolute contraindication because it im-
proves gas exchange, reduces the work of breathing and 
the need for intubation, decreases hospitalization dura-
tion and improves survival (Evidence A) [12]. NIV is 
effective in reducing the need for invasive mechanical 
ventilation and improving short-term survival in pa-
tients with severe AECOPD. Results from a large retro-
spective cohort study show that NIV given to patients 
on admission to hospital reduces in-patient mortality, 
shortens length of hospital stay and lowers costs com-
pared to those treated with invasive mechanical ventila-
tion [104]. 
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